RxDoctor Payments Data

Jennifer Syracuse

Family · Washington, DCNPI 1225300031

Payments from drug & device makers

$1,132in general payments, 2019–2025

Across 51 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$166
  • Amgen$165
  • Novo Nordisk$137
  • Novartis$133
  • Johnson & Johnson$126
  • Regeneron Healthcare Solutions, Inc.$72
  • plus $332 from 9 others

What the payments were for

  • Food & beverage$1,132100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,132 in reported general payments places this provider in the 80th percentile of 392 family providers in District of Columbia.

See all family providers in District of Columbia

Medicare billing

Part B allowed, 2024
$51,576
Medicare patients
325
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$182,090
JardianceEmpagliflozin45$66,897
EntrestoSacubitril/Valsartan37$48,976
Repatha SureclickEvolocumab26$28,323
XareltoRivaroxaban15$25,050
OzempicSemaglutide17$19,169
BrilintaTicagrelor15$7,365
Metoprolol Succinate159$2,974
Rosuvastatin Calcium136$2,594
Atorvastatin Calcium207$2,374
Ezetimibe83$2,009
Nebivolol Hcl22$1,268
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide15$1,242
Amlodipine Besylate112$1,001
Losartan Potassium75$824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$166$182,090119 claims
NovartisEntresto$133$48,97637 claims
Johnson & JohnsonXarelto$126$25,05015 claims
Novo NordiskOzempic$137$19,16917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 392 family providers in District of Columbia.

Other family in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →